Clinical Pharmacology · Respiratory Medications

Anticholinergic Inhalers

On this page 6 sections

In 30 seconds
The college version
Eli explains
Check yourself
Quick check
Study tools

In 30 seconds

Anticholinergic (antimuscarinic) inhalers block acetylcholine's M3 receptors on airway smooth muscle, relaxing the bronchi and drying up secretions. Ipratropium is the short-acting agent (SAMA) used for quick relief and exacerbations; tiotropium, umeclidinium, aclidinium, and glycopyrronium are long-acting agents (LAMAs) used for daily maintenance. Cholinergic tone drives much of the reversible airway narrowing in COPD, so this class is central to COPD therapy and a useful add-on in difficult asthma. Their quaternary ammonium chemistry keeps them mostly local to the lung, so side effects are dry mouth and irritation rather than whole-body anticholinergic toxicity.

The college version

Mechanism of action

The vagus nerve releases acetylcholine onto airway smooth muscle and glands via M3 muscarinic receptors, causing bronchoconstriction and mucus secretion. These drugs competitively block M3 receptors, preventing that contraction and secretion. This differs from beta-2 agonists, which relax muscle through a separate pathway, so the two classes combine well. Antimuscarinics treat airway "tone," not the inflammation targeted by corticosteroids or leukotriene modifiers.

Short-acting versus long-acting agents

Ipratropium (SAMA) has a fast onset and shorter duration, useful for as-needed relief and acute exacerbations. It is often combined with albuterol in one nebulizer solution or inhaler, since the two act on different receptors with additive effects; this pairing is a mainstay of emergency department management of COPD and asthma exacerbations. Tiotropium, umeclidinium, aclidinium, and glycopyrronium are LAMAs engineered for prolonged receptor binding, giving scheduled dosing that keeps airways open around the clock. LAMAs are not rescue drugs; they are foundational, scheduled therapy.

Role in disease management

In COPD, cholinergic tone is the most reversible contributor to airflow limitation, so LAMAs are core maintenance therapy at nearly every severity stage, often with a LABA. When risk remains elevated, prescribers add an inhaled corticosteroid for "triple therapy" (LAMA plus LABA plus inhaled corticosteroid), usually as one device. In asthma, anticholinergics are secondary add-on therapy for patients not controlled on inhaled corticosteroids and LABAs, not first-line treatment.

Systemic profile and local effects

Because these drugs are quaternary ammonium compounds with a permanent positive charge, they are poorly absorbed across the airway and gut, so little reaches systemic circulation and the tachycardia or central effects of older oral antimuscarinics are uncommon. Effects that occur are local: dry mouth, metallic taste, cough, and pharyngeal irritation. If aerosol reaches the eyes, as with a loose-fitting mask instead of a mouthpiece, patients can develop blurred vision, eye pain, or acute angle-closure glaucoma; urinary retention can occur if drug reaches the bladder outlet in susceptible patients.

Cautions and technique

Use cautiously in narrow-angle glaucoma and bladder outlet obstruction such as benign prostatic hyperplasia. A key rule: never combine a SAMA and a LAMA, since both act on the same receptors and stacking them only adds risk without benefit. Teaching should cover slow, coordinated inhalation technique, a mouthpiece rather than a mask for nebulized ipratropium, mouth rinsing after use, and prompt reporting of eye pain, vision changes, or urinary difficulty.

Eli explains

The same idea, in plain words

Explain it like I’m 10

Imagine your airways have a switch a nerve keeps flipping to "squeeze tight" and "make extra slime." The nerve talks to the muscle using a chemical key that fits a lock. Anticholinergic inhalers are a fake key that fits the lock but does not turn it, so the real messenger cannot get in and the muscle stops squeezing. Ipratropium is the fast, short-lived fake key for right-now help; tiotropium and its cousins are long-lasting fake keys used daily to keep airways calm. Because this fake key mostly stays inside the lungs instead of traveling the body, it usually just makes your mouth dry or gives a funny taste. But if mist gets in your eyes, like from a loose mask, it can blur your vision, so breathe it in through a mouthpiece, not a mask.

Check yourself

2 review questions from the chapter. Try each one, then open the answer.

A patient using nebulized ipratropium through a loose-fitting face mask reports blurred vision and eye discomfort after treatment. What likely happened, and what change in delivery would help prevent it?
Show answer
Mask-related eye exposure to nebulized ipratropium
Mist likely drifted into the patient's eyes through gaps in the mask, and switching to a mouthpiece would keep the drug directed into the airway instead of the eyes.
Explain why anticholinergic bronchodilators are considered central to COPD treatment but only a secondary, add-on option in asthma.
Show answer
Cholinergic tone dominates COPD but not asthma
In COPD, cholinergic signaling is the main reversible cause of airway narrowing, so blocking it gives a big, reliable benefit, whereas asthma is driven mainly by allergic inflammation that anticholinergics do not treat, so they help only as an add-on once inhaled corticosteroids and LABAs are not enough.

Quick check

3 questions here. Answers stay hidden until you check.

Question 1 of 3